12 results
To test the non-inferiority of the Synergy* abluminal coated everolimus eluting stent with bio-absorbable polymer from Boston Scientific compared to the Nobori* abluminal coated biolimus eluting stent with bio-absorbable polymer from Terumo in the…
The main objective of the present study is to investigate whether the ORSIRO coronary stent is non-inferior compared to the Xience coronary stent in patients with total coronary occlusions.
To determine the antileukemic activity of combination chemotherapy including bortezomib as reinduction therapy in childhood relapsed/refractory ALL.
The objective of the ABSORB PHYSIOLOGY is to evaluate the following in participants undergoing coronary artery scaffolding/stenting for significant coronary artery disease:• The acute (post-implantation) effect of an implanted BVS or mDES on…
Primary Objectives:-To evaluate if the treatment of Low Risk HB can be reduced (Group B1)-To compare different induction treatment regimens for Intermediate risk HB (Group C)-To compare different post induction treatment regimens for High Risk HB (…
Study Objectives:* To monitor the long-term safety profile of NI-0501* To assess HLH patients* survival after NI-0501 treatment* To assess duration of response to NI-0501 treatment (i.e. maintenance of HLH control)* To assess post-HSCT outcome…
This protocol will compare clinical outcomes of the SUPRAFLEX and XIENCE drug-eluting stents in a broad patient and lesion population and will gain substantial additional information on patients in a real world setting. These data will also provide…
To determine non-inferiority of preoperative 6 weeks of VCE to VAD in the overall metastatic rapid response rate (MetRR) in newly diagnosed stage 4 childhood renal tumours. The MetRR will include the pulmonary response rate (PRR) and the response…
Primary objective:-To increase 12 months DFS of DH/TH-HGBL patients in CMR after DA-EPOCH-R from 70% to 85% with nivolumab consolidation treatmentSecondary objectives:-To evaluate CMR rate after DA-EPOCH-R-To evaluate 18 months event free survival (…
The primary objective is reducing treatment-related morbidity and mortality without adversely impacting DFS in Ph+ ALL patients, classified as Standard Risk (SR) based on low minimal residual disease (MRD) at week 10-12 of therapy.Because there is…
The primary objective of ALLTogether is to improve survival and quality of survival in children and young adults with acute lymphoblastic leukaemia
The objective of the induction/consolidation chemotherapy randomisation (R1) is to compare: - VIDE strategy: vincristine, ifosfamide, doxorubicin and etoposide (VIDE) as induction chemotherapy and vincristine, actinomycin D and ifosfamide (VAI),…